VEGFA and non-small cell lung carcinoma: In 2006, the FDA approved the combination of paclitaxel, carboplatin, and bevacizumab (Avastin®, Roche, Basel, Switzerland), a recombinant humanized monoclonal IgG1 antibody selectively binding and neutralizing the human vascular endothelial growth factor (VEGF), for the first-line therapy of advanced nonsquamous non-small-cell lung carcinoma [119].